Anatomic Pathology Market Outlook:
Anatomic Pathology Market size was valued at USD 24.3 billion in 2024 and is projected to reach USD 56.4 billion by the end of 2037, rising at a CAGR of 6.4% during the forecast period, 2025 to 2037. In 2025, the industry size of anatomic pathology is estimated at USD 26.5 billion.
The anatomic pathology industry is set to rise with an increase in the patient base globally. Hence, there will be over 31 million cancer cases yearly, requiring for the increase in diagnostic capability. The supply chain for AP goods, including automated staining systems, reagents, and biopsy tools, largely depends on global trade, especially for APIs and parts for medical devices. Along with USD 852 million worth of diagnostic reagents and histology equipment, the U.S. imports USD 1.3 billion worth of pathology-related medical devices annually. This import is primarily operated from primarily from China, Japan, and Germany, and exports USD 860 million worth of these devices.
In 2024, government and institutional investments in anatomic pathology research, development, and deployment (RDD) totaled USD 3.9 billion globally, with the U.S. National Institutes of Health spending USD 1.4 billion to cancer diagnostics innovation. The Horizon Europe initiative has allocated €621 million for AI integration and digital pathology. Trade imbalances still exist in raw materials, particularly in formaldehyde and paraffin. Furthermore, nearly 46% of worldwide exports of raw materials come from China. However, 67% of the microtomes components are sourced from Southeast Asia, but the majority of automated staining system assembly is still done domestically in the U.S and Germany.
